Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this free, full length talk
Topics Covered
- Differences in the structure and biological properties of SARS-CoV-2 Spike proteins compared to those of other coronaviruses (including SARS)
- The distinct profile of the distribution of SARS-CoV-2-infected cells, particularly in lung and epithelial tissue, compared to other coronaviruses
- SARS-CoV-2’s Spike protein sequence grants it the unique ability to interact with Neuropilin-1, in addition to ACE2
- Role of Neuropilin-1, a cell-surface co-receptor, in facilitating mechanisms of SARS-CoV-2 entry into cells
- Current understanding of the influence of Neuropilin-1 on the development of COVID-19 and on disease progression
- The potential of developing SARS-CoV-2-specific antiviral drugs targeting Neuropilin-1.
Biography
Yohei Yamauchi became fascinated by viral escape mechanisms of host immunity early on during his studies at Nagoya University Medical School, where he initiated his research into virus-host interactions at the Department of Virology. After 2 years of clinical residency, he acquired his PhD in Molecular Virology from Nagoya University Graduate School of Medicine in 2008. That same year, Dr Yamauchi joined ETH Zurich in Switzerland to take his research further, investigating the cell biology of influenza viral entry. His work in Zurich identified important host cell factors for viral entry, particularly with respect to viral uncoating mechanisms. Dr Yamauchi then joined the University of Bristol as an Associate Professor in 2016 focusing on viral cell biology. In response to the COVID-19 pandemic, Dr Yamauchi began work on SARS-CoV-2, whilst maintaining his investigative focus on understanding the cell biology and mechanisms of virus host-cell entry.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Yamauchi, Y. (2021, February 24). The role of Neuropilin-1 as a SARS-CoV-2-specific endocytosis potentiator [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/POHL7782.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Yohei Yamauchi has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
The role of Neuropilin-1 as a SARS-CoV-2-specific endocytosis potentiator
Other Talks in the Playlist: Interviews on Covid-19
Transcript
Quiz
Disclaimer: This quiz is intended for learning assessment purposes only and does not grant any certification or credit.
If you are interested in getting a certificate for watching the talk, follow the instructions in this talk's Accreditation Information (where available.)